Synchrony Medical announced it has secured a $1 million investment from the New Jersey Innovation Evergreen Fund (NJIEF), with the capital matching an investment from Edge Medical Ventures. The company said the funding will be used to accelerate U.S. commercial operations, support ongoing clinical research and product development, and broaden patient access to its LibAirty at-home airway clearance system through respiratory clinics, hospitals, and homecare networks nationwide.
LibAirty is an FDA-cleared airway clearance system that pairs guided breathing with synchronized, targeted chest compressions to help patients clear lung secretions during a short daily treatment performed at home. Synchrony positioned the system as an option for people living with chronic respiratory conditions including chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis, where routine airway clearance can help prevent exacerbations, reduce hospitalizations, and improve quality of life.
The company said clinical studies have shown LibAirty delivered superior sputum clearance and improved user comfort compared with conventional airway clearance devices. Synchrony also said the technology was developed in collaboration with pulmonologists at Sheba Medical Center and was inspired by established airway clearance techniques.
NJIEF is described as a public-private partnership under the New Jersey Economic Development Authority (NJEDA) intended to attract, anchor, and scale companies commercializing innovative technologies in the state. Edge Medical Ventures, identified as an NJIEF Qualified Venture Fund partner, said Synchrony reflects the type of clinically validated medtech company the co-investment model is designed to support.
Synchrony said it has established its U.S. headquarters in Jersey City, New Jersey, and maintains additional operations in Or Yehuda, Israel. The company was founded at the MEDX Xelerator venture studio supported by the Israeli Innovation Authority.
KEY QUOTES:
“Synchrony’s vision is to fundamentally change how chronic lung disease is treated at home. With the backing of strong partners like Edge Medical and the NJIEF, we have established our U.S. headquarters in New Jersey, home to one of the most dynamic health innovation ecosystems in the country. This additional funding accelerates our ability to scale U.S. commercial activity and expand patient access to LibAirty nationwide, while continuing to innovate.”
Anat Shani, CEO, Synchrony Medical
“Synchrony’s LibAirty system combines both strong clinical validation and real-world usability, serving as a successful proof-of-concept for our co-investment model with NJEDA. We are already seeing clear signs of commercial traction and believe Synchrony is well positioned to lead the airway clearance market.”
Shai Policker, Managing Partner, Edge Medical Ventures
